AGM 2007

Oxford Biomedica PLC
03 May 2007




For Immediate Release                                                3 MAY 2007




                  OXFORD BIOMEDICA ANNUAL GENERAL MEETING 2007



Oxford, UK: 3 May 2007: Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that all resolutions were duly passed at its Annual
General Meeting, held today in London.


                                     -Ends-
                                        


For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive            Tel: [phone]

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson        Tel: [phone]
Buchanan Communications

Scientific/Trade Press Enquiries:
Gemma Price/ Holly Griffiths/ Katja Stout           Tel: [phone]
Northbank Communications



Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development and commercialisation of novel therapeutic vaccines and gene-based
therapies with a focus on the areas of oncology and neurotherapy. The Company
was established in 1995 as a spin-out from Oxford University, and is listed on
the London Stock Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. In oncology, the lead product candidate
is TroVax(R), an immunotherapy for multiple solid cancers, which is being
developed and commercialised in collaboration with Sanofi-Aventis. TroVax is in
Phase III development for renal cancer and Sanofi-Aventis is implementing a
development plan for colorectal cancer. Oxford BioMedica's oncology pipeline
includes a specific immunotherapy candidate, Hi-8(R) MEL, for melanoma, which
has completed two clinical trials. In neurotherapy, the Company's lead product,
ProSavin(R), is expected to enter clinical development for Parkinson's disease
in 2007. The neurotherapy pipeline also includes preclinical gene-based
therapeutics for vision loss, motor neuron disease and nerve repair. In
addition, the Company has a platform technology for therapeutic vaccines for
infectious diseases.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 75 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Corporate
partnerships include the collaboration on TroVax with Sanofi-Aventis and on a
targeted antibody therapy with Wyeth. Intervet, Sigma-Aldrich, Viragen, MolMed
and Virxsys are also corporate partners. Technology licensees include Merck &
Co, Biogen Idec, GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange
            AAUPMGGW